Tema Heart & Health ETF holds a quantitatively derived Neutral Morningstar Medalist Rating. The rating suggests the model does not express a clear expectation of outperformance or underperformance relative to peers over a full market cycle.
Tema Heart & Health ETF HRTS
Morningstar’s Analysis HRTS
Will HRTS outperform in the future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
Parent Pillar
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings 48.3
|
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
|---|---|---|---|
Eli Lilly and Co | 11.51 | 6M | Healthcare |
Thermo Fisher Scientific Inc | 5.64 | 3M | Healthcare |
UnitedHealth Group Inc | 4.67 | 2M | Healthcare |
Merck & Co Inc | 4.37 | 2M | Healthcare |
Novo Nordisk AS Class B | 4.13 | 2M | Healthcare |
Revolution Medicines Inc Ordinary Shares | 3.84 | 2M | Healthcare |
Roche Holding AG ADR | 3.82 | 2M | Healthcare |
Johnson & Johnson | 3.63 | 2M | Healthcare |
Cytokinetics Inc | 3.40 | 2M | Healthcare |
Gilead Sciences Inc | 3.28 | 2M | Healthcare |